INDOUS
Indo Us Biotech financials
- Market cap
- ₹157 Cr
- Sector
- Fast Moving Consumer Goods
Quarterly results
Q1 FY27: revenue up 7.2%, net profit down 35.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 24 | 33 | 31 | 31 +39% | 23 −3% | 26 −22% | 33 +7% |
| EBITDA | 5 | 6 | 5 | 5 | 4 −19% | 4 −25% | 3 −29% | 4 −27% |
| Net profit | 4 | 5 | 4 | 5 | 3 −21% | 3 −41% | 2 −46% | 3 −35% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −47.2% 1Y
1Y: ₹148.24 on 10 Sept 2025 → ₹78.24. High ₹150.72 (20 Feb 2026), low ₹77.48 (4 Sept 2026).
Financials, as filed
Revenue grew 21.4% a year over 3 years, FY23 to FY26. Operating margin held at 15.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹62 Cr | ₹73 Cr | ₹104 Cr | ₹110 Cr |
| Operating profit | ₹9 Cr | ₹11 Cr | ₹19 Cr | ₹17 Cr |
| Operating margin | 15.2% | 14.8% | 18.2% | 15.4% |
| Interest | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| Depreciation | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹7 Cr | ₹8 Cr | ₹16 Cr | ₹13 Cr |
| Net margin | 11.7% | 11.3% | 15.7% | 11.9% |
| Cash from operations | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹-13 Cr |
| Free cash flow | ₹-1 Cr | ₹0 Cr | ₹1 Cr | ₹-15 Cr |
| ROCE | 15.0% | 14.0% | 21.0% | 14.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹6 Cr | ₹9 Cr | ₹10 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
| Reserves | ₹15 Cr | ₹30 Cr | ₹44 Cr | ₹43 Cr | ₹67 Cr | ₹72 Cr |
| Borrowings | ₹11 Cr | ₹12 Cr | ₹12 Cr | ₹14 Cr | ₹28 Cr | ₹37 Cr |
| Other liabilities | ₹11 Cr | ₹4 Cr | ₹3 Cr | ₹7 Cr | ₹3 Cr | ₹4 Cr |
| Total liabilities | ₹44 Cr | ₹56 Cr | ₹69 Cr | ₹84 Cr | ₹117 Cr | ₹133 Cr |
| Fixed assets | ₹2 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹10 Cr | ₹11 Cr |
| Capital work in progress | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹39 Cr | ₹48 Cr | ₹61 Cr | ₹74 Cr | ₹108 Cr | ₹121 Cr |
| Total assets | ₹44 Cr | ₹56 Cr | ₹69 Cr | ₹84 Cr | ₹117 Cr | ₹133 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −1.89 pp while the public added +1.87 pp. The shareholder count grew 51% to 4,690.
- Promoters
- 68.3%
- FIIs
- 0.0%
- Public
- 31.7%
Since Jun 2025
- Promoters −1.89 pp
- Public +1.87 pp
- FIIs +0.01 pp
How it drifted, 12 quarters
Over this window promoters fell from 70.2% to 68.3% — −1.9 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 70.2%, Public 29.8%.Dec '23: Promoters 70.2%, Public 29.8%.Mar '24: Promoters 70.2%, Public 29.8%.Jun '24: Promoters 70.2%, Public 29.8%.Sep '24: Promoters 70.2%, Public 29.8%.Dec '24: Promoters 70.2%, Public 29.8%.Mar '25: Promoters 70.2%, Public 29.8%.Jun '25: Promoters 70.2%, Public 29.8%.Sep '25: Promoters 70.2%, Public 29.8%.Dec '25: Promoters 70.2%, Public 29.8%.Mar '26: Promoters 68.3%, FIIs 0.2%, Public 31.5%.Jun '26: Promoters 68.3%, FIIs 0.0%, Public 31.7%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Indo Us Biotech Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Jagdishkumar Devjibhai Ajudiya | 48.82% | unchanged |
| Indo Us Agriseeds Limited | 8.82% | unchanged |
| Ajudia Jagdish Devjibhai Huf | 5.74% | unchanged |
| Malti Jagdishbhai Ajudia | 2.91% | unchanged |
| Improwised Technologies Private | 1.99% | unchanged |
| Priyanka Jagdishbhai Ajudia | 1.99% | unchanged |
| Bhartiben Rajendra Gandhi | 1.50% | unchanged |
| Pratik Rajendrabhai Gandhi | 1.50% | unchanged |
| Aumit Capital Advisors Limited | 1.19% | unchanged |
| Natvarsinh T Chavda . | 1.02% | unchanged |
| Hinaben Nileshbhai Patel | 0.00% | unchanged |
| Samarth Nileshbhai Patel | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹78, this stock must grow earnings at 5% every year for 7 years. Our analysis caps realistic growth at ~21%. At that growth it is worth ₹181 — upside of 132%.
- Growth the price implies
- 5.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 21.9% a year
- net profit, FY23–FY26 · EPS 21.0%
- The gap
- -0.2 pp
- 132% downside if it only repeats history
Learn to analyse Indo Us Biotech Limited
Guides on how to read this kind of business and the numbers that matter.